tbuckley/cabot-search huggingface dataset:
Trastuzumab plus gemcitabine and cisplatin chemotherapy for HER2/neu-overexpressing breast cancer with visceral metastasis
Authors: A. A. Elsaid, Y. Elkerm, K. El-Shami
Journal: Journal of Clinical Oncology (2008)

1109 Background: Trastuzumab provides significant clinical benefits in HER2-positive metastatic breast cancer patients when administered in combination with chemotherapy. This single arm phase II trial evaluated the safety and efficacy of adding trastuzumab to a combination of gemcitabine and cisplatin as 2nd line in patients with visceral metastasis from HER2-positive breast cancer. Methods: Patients with previously treated stage IV (with visceral metastasis) from HER2-positive breast cancer received up to six 21- day cycles of gemcitabine 1,000 mg/m2 (days 1 and 8) and cisplatin 35 mg/m2 (days 1 and 8) as well as trastuzumab 4 mg/kg intravenously followed by 2 mg/kg/week i.v. until progression. Results: Forty patients were recruited, all of whom had previously received chemotherapy (24 pre-treated with taxanes, 16 pre-treated with anthracyclines). A median of six cycles of the study treatment was delivered. The overall objective response rate of 60% (24/40 patients) including 8 patients achieving a complete response (20%). The clinical benefit rate (complete response + partial response + stable disease) was 85%. Median time to progression was 13.2 months, and median overall survival was 22 months. Toxicity included 2 patients of grade 4 hematologic toxicity. Transient and reversible elevation of liver enzymes was noted in 20%of patients. Infection without severe grade 4 neutropenia was observed in three cases. No nonhematologic toxicity was beyond grade I was noted and there was no treatment-related deaths. Conclusions: Combination chemotherapy with gemcitabine and cisplatin plus trastuzumab is well tolerated and active in patients with visceral metastasis from HER2 overexpressing breast cancer, even after prior exposure to anthracyclines and taxanes. Addition of trastuzumab to gemcitabine-cisplatin was well tolerated and trastuzumab did not seem to exacerbate the known toxicity of gemcitabine and cisplatin. Symptomatic cardiotoxicity was observed in 2 trastuzumab-treated patients. Gemcitabin-cisplatin-trastuzumab appears to be a safe and active combination in visceral metastasis from HER2/positive breast cancer. These observations warrant its further testing in randomized studies. No significant financial relationships to disclose.
P0375 : The validation of Hong Kong Liver Cancer staging system and comparision with Barcelona Clinic Liver Cancer for prediction of survival and treatment in hepatocellular carcinoma patients
Authors: H.R. Kim, J.H. Kim, Y.J. Yoo, S.H. Kang, Y.S. Lee, S.J. Suh, Y.K. Jung, Y.S. Seo, H.J. Yim, J.E. Yeon, K.S. Byun
Journal: Journal of Hepatology (2015)
Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
Authors: Yorihisa Kitagawa, Hiroyuki Shimada, Ryusaburo Mori, Kouji Tanaka, Mitsuko Yuzawa
Journal: Ophthalmology (2016)
Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck
Authors: G. Catimel, J. Verweij, V. Mattijssen, A. Hanauske, M. Piccart, J. Wanders, H. Franklin, N. Le Bail, M. Clavel, S.B. Kaye, T. Cerny, H.H. Hansen, S. Kaplan, M. Marty, N. Pavlidis, H.J. Schmoll, C. Sessa, P. Siegenthaler, W. Ten Bokkel Huinink, A.T. Van Oosterom, J.B. Vermorken
Journal: Annals of Oncology (1994)
Correlation of preoperative citology/histology in radiologically detected lesions and histologic findings at excision
Authors: P. Manente, G. Vicario, E. Scelzi, L. Sartor, L. Nicolardi, A. Rizzo, A. Pinarello, B. Spaliviero, R. Sbeghen
Journal: Journal of Clinical Oncology (2007)

1552 Background: The major techniques used to diagnose breast abnormality has been for many years fine-needle aspiration (FNA) cytology and core needle biopsy (CNB) and more recently vacuum-assisted core biopsy (VACB). These techniques are accurate and allow definitive therapeutic surgery. The aim of our study was to detemine whether cytology/histologic findings mach histologic findings at excision. Methods: In our Institution, between January 2004 and June 2006, 43,138 mammographic exams were performed. 1,012 patients had patological lesions at mammography: 617 FNA cytology ( C due to European guidelines for breast cancer screening assessment) and 395 CNB/VACB (B) were performed. Patients with respectively suspicious and malignant FNA cytology (C4 and C5) and respectively uncertain malignant potential, suspicious and malignant histology (B3, B4 and B5) underwent to surgery. Results: The number of cancer identified by FNA cytology was 158 and the number of cancer identified by CNB/VACB was 253. The correlation of preoparative citology/histology with definitive histology had showed: false negative rate respectively 0.79% for histology (B) and 3.16% for cytology (C). False positive rate was respectively 0.4% for B and 0.63 for C. Complete sensitivity was 98.2% for B and 89.87% for C. Absolute sensitivity was 90.51% for B and 76.58% for C. Conclusions: Our data demostrated very high performance of diagnostic preoperative procedures due to multidisciplinary approach between the radiologists, the clinicians and the pathologists. No significant financial relationships to disclose.
Paradoxical decrease in isoprostane and increase in superoxide dismutase following CPAP withdrawal in OSA
Authors: Denis Monneret, Dominique Bonnefont-Rousselot
Journal: European Respiratory Journal (2016)

Stradling et al . [1] have recently published an interesting, unprecedented study assessing the effects of a continuous positive airway pressure (CPAP) withdrawal on oxidative stress in patients already treated for moderate-to-severe obstructive sleep apnoea (OSA). Based on a combination of two different studies, the authors showed that stopping CPAP for 2 weeks ("sham-CPAP" group) significantly decreased the urinary F2-isoprostane concentration, while it increased the activity of the blood superoxide dismutase (SOD), compared with uninterrupted treatment ("CPAP" group). The fall in urinary F2-isoprostane concentration observed in patients who returned to OSA was contrary to the hypothesis tested by the authors, i.e. an increase in oxidative stress when the disease returns. Interestingly, these paradoxical results are corroborated by the strong negative correlation they found between the re-increased oxygen desaturation index values after 2 weeks of CPAP withdrawal and the fall in urinary F2-isoprostane concentration. The authors advanced the hypothesis that intermittent hypoxia for 2 weeks of CPAP withdrawal may have caused a preconditioning protection against oxidative stress. A comment about the paradoxical variations in oxidative stress biomarkers following CPAP withdrawal in OSA <http://ow.ly/Uc33R>
Determination of real-time tumor oxygenation changes following high-dose radiotherapy in orthotopic and subcutaneous lung cancers in mice
Authors: Changhoon Song, Beom-Ju Hong, Seoyeon Bok, Chan-Ju Lee, Young-Eun Kim, Sang-Rok Jeon, Yun-Sang Lee, Gi Jeong Cheon, Jin Chul Paeng, G-One Ahn, Hak Jae Kim
Journal: Journal of Thoracic Oncology (2016)
Prediction of Early Recurrence After Acute Ischemic Stroke
Authors: E. Murat Arsava, Gyeong-Moon Kim, Jamary Oliveira-Filho, Levent Gungor, Hyun Jin Noh, Morgana de Jesus Lordelo, Ross Avery, Ilko L. Maier, Hakan Ay
Journal: JAMA Neurology (2016)

Approximately half of recurrent strokes occur within days and weeks of an ischemic stroke. It is imperative to identify patients at imminent risk of recurrent stroke because recurrent events lead to prolonged hospitalization, worsened functional outcome, and increased mortality.To test the validity of a prognostic score that was exclusively developed to predict early risk of stroke recurrence in a multicenter setting.This hospital-based cohort study examined patients with and without magnetic resonance imaging-confirmed recurrent stroke within 90 days after an ischemic stroke. The study was performed at 3 teaching hospitals in the United States, Brazil, and South Korea and comprised adult patients admitted within 72 hours of symptom onset with a magnetic resonance imaging-confirmed diagnosis of acute ischemic stroke. Recruitment to the US cohort was performed from June 1, 2009, through April 30, 2011. Recruitment to the Korean and Brazilian cohorts was performed from January 1, 2007, through December 31, 2011. Data analysis was performed from June 1, 2013, to December 31, 2014.The primary outcome was recurrent ischemic stroke as defined by a clinical incident that was clearly attributable to a new area of brain infarction occurring within the 90 days of index infarction. An investigator who was masked to the patient's recurrence status calculated the Recurrence Risk Estimator (RRE) score for each patient based on information available after initial line of testing in the emergency department. We assessed the predictive performance of the RRE by computing the area under the receiver operating characteristic curve.The study included 1468 consecutive patients with 59 recurrent ischemic stroke events. The median age of the patients was 69 (interquartile range, 58-79) years, and 633 (43.1%) were female. The cumulative 90-day recurrence rate was 4.2% (95% CI, 3.2%-5.2%). The mean RRE score was 2.2 (95% CI, 1.9-2.5) in patients with recurrence and 1.0 (95% CI, 1.0-1.1) in patients without. The risk of recurrence increased with a higher RRE score (log-rank test, P < .001). The area under the receiver operating characteristic curve for discrimination was 0.76 (95% CI, 0.70-0.82). The RRE identified 710 patients (48.4%) in the study population as high risk (>10%) or low risk (<1%). The sensitivity and specificity were 38% and 93% for identifying low-risk subsets and 41% and 90% for identifying high-risk subsets, respectively.This study confirms the validity of the RRE score in a multicenter cohort of patients with diverse characteristics. Our findings suggest that the RRE could be useful in identifying high- and low-risk patients for targeted stroke prevention.
The Course of Illness After Initial Diagnosis of Major Depression
Authors: Richard C. Shelton
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study
Authors: Paula Marlton, John F Seymour, Kenneth Bradstock, Ian D Lewis, Russell Saal, Lyle McMillen, Juliana Di Iulio, Diana Zannino, Andrew Grigg
Journal: Blood (2013)
Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a
Authors: Vincent Pedergnana, David Smith, Paul Klenerman, Eleanor Barnes, Chris C. A. Spencer, M. Azim Ansari
Journal: Hepatology (2016)

This work is funded by a grant from the Medical Research Council (STOP‐HCV Consortium MR/K01532X/1) and a grant from the Wellcome Trust WT091663MA. Potential conflict of interest: Nothing to report. E.B. is funded by the MRC as an MRC Senior Clinical Fellow, as well as Oxford NIHR BRC. E.B., P.K, and C.C.A.S. are part of the STOP‐HCV Consortium. Author names in bold designate shared co‐first authorship. TO THE EDITOR: Peiffer et al. recently reported1 an association between the host interferon lambda 4 (INFL4) single‐nucleotide polymorphism (SNP), rs12979860, and the NS5A resistance‐associated variant (RAV) Y93H in hepatitis C virus (HCV) genotype 1b (HCVg1b). This observation is intriguing because it directly links innate immunity to HCV viral drug resistance for the first time. A small cohort of (51) HCV genotype 3 (HCVg3) patients was included in the analysis; this subgroup analysis was underpowered and no association was observed in HCVg3. The association was also not observed in 259 patients with HCV subtype 1a. HCVg3 infections are more difficult to treat with direct‐acting antivirals. The reason for this is unknown, but could be explained by a distinct pattern of RAVs and an increase in the prevalence of "favorable" IFNL4 SNPs in this genotype. Here, we used a large cohort of 496 HCVg3a‐infected patients (from the BOSON clinical study2) and report no significant association (P > 0.05) between the treatment‐beneficial C/C genotype of INFL4 and RAV site Y93H in the NS5A gene. Using next‐generation sequencing,3 baseline viral sequences from 556 BOSON patients chronically infected with either HCVg2 or HCVg3 were obtained. The INFL4 SNP rs12979860 was also genotyped. The cohort (total of 556) was composed of 49 (8.8%) HCVg2‐ and 507 (91.2%) HCVg3‐infected patients, of which 496 (89.2%) were subtype 3a. Substitutions in the quasi‐species at Y93 (Y93H) were only observed in HCVg3a‐infected patients; therefore, the analysis was done on this subset of the data. The Y93H RAV was present in 11.1% (55 of 496) of the genotype 3a–infected patients; in 4.7% (23 of 496), Y93H was as the majority variant. There was no significant association between the presence of H (either as the consensus level or at any level of detection) and the beneficial C/C genotype of INFL4 (P > 0.05; Table 1). Overall, our data support the Peiffer et al. hypothesis that the association between INFL4 and Y93H is specific to HCV genotype 1b. Table 1 - Prevalence of Y93H RAV in HCVg3a‐Infected Patients (n=496) Stratified by rs12979860 IFNL4 SNP Y93H: Consensus Level n/N (%) Y93H: All Types n/N (%) INFL4 C/C 12/184 (6.5) 25/184 (13.5) INFL4 non C/C 11/312 (3.5) 30/312 (9.6)
US hospitals make progress against healthcare associated infections
Authors: Michael McCarthy
Journal: BMJ (2016)

US hospitals have made progress in preventing healthcare associated infections, but such infections remain common and are often caused by difficult to treat, antibiotic resistant organisms, a study by the Centers for Disease Control and Prevention (CDC) has found.1

Researchers compared the number of infections reported in 2014 with a predicted number of infections based on historical baselines established over several years for central line associated bloodstream infections, surgical site infections, catheter associated urinary tract infections, and Clostridium difficile infections. The study was reported in the CDC’s Morbidity and Mortality Weekly Report and …
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Authors: Massimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, Jungsil Ro, Seock-Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, Maria Koehler, Dennis Slamon
Journal: The Lancet Oncology (2016)
Photodynamic therapy: shining light where it is needed.
Authors: E Glatstein, D I Rosenthal
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.10.1844 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8410108 Photodynamic therapy: shining light where it is needed. E GlatsteinxE GlatsteinSearch for articles by this author , D I RosenthalxD I RosenthalSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.10.1844 PDF "Photodynamic therapy: shining light where it is needed.." Journal of Clinical Oncology, 11(10), pp. 1844–1845© 1993 by American Society of Clinical Oncology
Total-Body Irradiation and Melphalan Is a Safe and Effective Conditioning Regimen for Autologous Bone Marrow Transplantation in Children With Acute Myeloid Leukemia in First Remission
Authors: F. Bonetti, M. Zecca, A. Pession, C. Messina, D. Montagna, E. Lanino, F. Fagioli, N. Santoro, A. Prete, S. Cesaro, R. Rondelli, G. Giorgiani, P. De Stefano, F. Locatelli
Journal: Journal of Clinical Oncology (1999)

PURPOSE: To evaluate the safety and efficacy of a preparative regimen consisting of fractionated total-body radiation (9.9 to 12 Gy) and melphalan (140 mg/m 2 in a single dose) in children with acute myeloid leukemia in first complete remission (CR) given autologous bone marrow transplantation (ABMT). PATIENTS AND METHODS: Fifty-three children (30 males and 23 females; age range, 1.5 to 18 years) were enrolled onto the study. The median time from first CR to ABMT was 3.5 months (range, 1.4 to 13 months), with 45 patients (85%) undergoing transplantation within 6 months from the diagnosis. Forty-five patients received in vitro marrow purging with standard-dose mafosfamide (100 μg/mL), seven patients were treated with interleukin-2 before marrow collection, and in the remaining child, the marrow was unmanipulated. The median infused cell dose was 1.8 × 10 8 /kg (range, 0.4 to 5.8 × 10 8 /kg). RESULTS: All patients but one achieved hematopoietic engraftment, with a median time to neutrophil recovery of 24 days (range,11 to 66 days). Treatment-related toxicity was moderate and consisted mainly of mucositis. One patient died from cytomegalovirus interstitial pneumonia, and one died from pulmonary hemorrhage. Fourteen patients (26%) relapsed at a median time of 6 months after ABMT (range, 2 to 17 months), with a cumulative relapse probability of 29% (95% confidence interval, 16% to 42%). The 5-year Kaplan-Meier estimate of survival for all 53 patients was 78% (range, 65% to 90%), whereas the overall 5-year disease-free survival was 68% (range, 55% to 81%), with a median follow-up duration of 40 months (range, 7 to 130 months). CONCLUSIONS: These data suggest that, in our cohort of patients, the combination of total-body irradiation and melphalan is safe and associated with good antileukemia activity, making ABMT an appealing alternative for postremission therapy in children with acute myeloid leukemia in first CR.
On Diploid Cell Lines 1 2
Authors: T. C. Hsu, John E. K. Cooper
Journal: JNCI Journal of the National Cancer Institute (1974)

Several types of tissues (lung, kidney, bone marrow, and skin) from 2 subhuman primate species, the rhesus macaque and the African green monkey, were used to initiate primary cultures and propagated in vitro to determine the feasibility of the establishment of "longterm" diploid cell lines.. Most skin lines can be propagated for over 40 subculture generations (passages) and maintain a chromosome constitution like that of the primary cultures. Instead of reliance on a single cell source such as the WI-38 line, more diploid cell lines from human and subhuman primate sources should be made available for biomedical research and for pUblic health work.
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial
Authors: Zobair M. Younossi, Maria Stepanova, Jordan Feld, Stefan Zeuzem, Ira Jacobson, Kosh Agarwal, Christophe Hezode, Fatema Nader, Linda Henry, Sharon Hunt
Journal: Journal of Hepatology (2016)
Thymidine as a Chemotherapeutic Agent: Pharmacologic, Cytokinetic, and Biochemical Studies in a Patient With T-Cell Acute Lymphocytic Leukemia&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: S B Howell, B Chu, J Mendelsohn, D A Carson, F H Kung, J E Seegmiller
Journal: JNCI Journal of the National Cancer Institute (1980)

Biochemical studies suggested that leukemia T-cells have low levels of TTP-catabolizing enzyme activity and are uniquely sensitive to thymidine (dThd). A child with T-cell acute lymphocytic leukemia (ALL), whose peripheral blood lymphoblasts manifested very low TTP catabolic capacity, was treated with 75 g dThd/m2/day by constant iv infusion for two courses of 5 and 8 days. The dThd caused an initial accumulation of peripheral blood blasts in S-phase at the expense of cells in G1, followed by a rapid reversal of this pattern consistent with a block in late G1 and/or early S. Concurrently, a prompt reduction of blasts was found in the peripheral blood. However, dThd treatment neither decreased the number of lymphoblasts in the cerebrospinal fluid (CSF) nor cleared the marrow. No major toxicity was observed, but the effect of dThd on normal marrow elements could not be evaluated in this patient. Blood concentrations of dThd were 1.4-3.0 mM, and concentrations of thymine were in the same range; beta half-life for dThd was 48 minutes. Steady-state CSF dThd was 9% of the simultaneous serum level. Clearance measurements demonstrated that catabolism of dThd was saturated and that renal clearance was a major determinant of total body clearance during high-dose dThd infusion. A good correlation was found between biochemical and cytokinetic parameters and response to dThd for the peripheral blood lymphoblasts. However, dThd did not produce a useful remission in this case of T-cell ALL.
Activation of Carcinogenic Arylhydroxamic Acids by Human Tissues&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: C M King, C W Olive, R A Cardona
Journal: JNCI Journal of the National Cancer Institute (1975)

Incubation of the carcinogenic arylhydroxamic acids N-hydroxy-N-2-fluorenylacetamide or N-hydroxy-N-4-biphenylacetamide and tRNA with 105,000 times g supernatants of homogenates of human small intestine, liver, or colon led to formation of arylamine-substituted nucleic acid adducts. These data indicated that enzymes of human tissues could activate arylhydroxamic acids by N leads to O acyl transfer. The unstable N-acetoxyarylamines formed by these enzymes reacted spontaneously with the tRNA to give covalently linked adducts with the nucleic acid.